Amphastar Pharmaceuticals (AMPH) Amortization of Deferred Charges (2019 - 2026)
Amphastar Pharmaceuticals has reported Amortization of Deferred Charges over the past 7 years, most recently at $866000.0 for Q4 2025.
- For Q4 2025, Amortization of Deferred Charges rose 19.61% year-over-year to $866000.0; the TTM value through Dec 2025 reached $2.6 million, down 31.78%, while the annual FY2025 figure was $3.4 million, 44.38% down from the prior year.
- Amortization of Deferred Charges for Q4 2025 was $866000.0 at Amphastar Pharmaceuticals, up from $500000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $5.2 million in Q3 2023 and troughed at -$2.3 million in Q4 2021.
- A 5-year average of $962210.5 and a median of $724000.0 in 2024 define the central range for Amortization of Deferred Charges.
- Biggest five-year swings in Amortization of Deferred Charges: plummeted 334.58% in 2021 and later soared 9610.0% in 2023.
- Year by year, Amortization of Deferred Charges stood at -$2.3 million in 2021, then soared by 101.33% to $30000.0 in 2022, then soared by 9610.0% to $2.9 million in 2023, then plummeted by 75.15% to $724000.0 in 2024, then increased by 19.61% to $866000.0 in 2025.
- Business Quant data shows Amortization of Deferred Charges for AMPH at $866000.0 in Q4 2025, $500000.0 in Q3 2025, and $500000.0 in Q2 2025.